Full text is available at the source.
Diabetes, obesity & metabolism··
A long-lasting gut hormone treatment improves digestion tolerance of another diabetes therapy
Updated
Related papers
Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 106 papers
journal article
Nov '18
LY3298176, a new drug that activates two hormone receptors to treat type 2 diabetes: from discovery to early clinical testing
top 5% journal
cited by 763 papers
randomized controlled trial
Apr '25
Blood pressure lowering effects of combined GIP and GLP-1 receptor activators compared to GLP-1 activators alone
cited by 1 paper
journal article
Jun '25
How Glucagon-Like Peptides and Their Receptor Activators Help Manage Heart, Kidney, and Metabolic Conditions
top 30% journal
cited by 1 paper
journal article
Nov '24
Why combining GLP-1 with GIP and/or GCG agonists causes more weight loss than GLP-1 alone in obese adults without diabetes
top 5% journal
cited by 17 papers
journal article
Jun '17
A new GIP-like drug, ZP4165, boosts weight loss and blood sugar control caused by GLP-1 in rodents
cited by 113 papers
comparative study
Oct '20
Tirzepatide: a new drug that activates two hormones to help treat type 2 diabetes
cited by 60 papers
research support, non-u.s. gov't
Sep '25
GLP-1 and GIP drugs for diabetes and obesity may increase indigestion
📖 top 20% journal
cited by 1 paper
journal article